Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Accounts Payables (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Accounts Payables for 4 consecutive years, with $3.7 million as the latest value for Q4 2025.

  • For Q4 2025, Accounts Payables rose 14.44% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, up 14.44%, while the annual FY2025 figure was $3.7 million, 14.44% up from the prior year.
  • Accounts Payables was $3.7 million for Q4 2025 at Day One Biopharmaceuticals, down from $5.8 million in the prior quarter.
  • The five-year high for Accounts Payables was $16.0 million in Q4 2022, with the low at $439000.0 in Q2 2022.
  • Historically, Accounts Payables has averaged $4.4 million across 4 years, with a median of $3.9 million in 2022.
  • Biggest YoY gain for Accounts Payables was 939.86% in 2023; the steepest drop was 83.85% in 2023.
  • Over 4 years, Accounts Payables stood at $16.0 million in 2022, then crashed by 83.85% to $2.6 million in 2023, then increased by 26.63% to $3.3 million in 2024, then rose by 14.44% to $3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $3.7 million in Q4 2025, $5.8 million in Q3 2025, and $5.1 million in Q2 2025.